Dr. Reddy's Laboratories Limited

Dr Reddys Laboratories Ltd share price softened by 1.17% to Rs 1224.5. The Company's net profit jumped 109.64% to Rs 913.2 crore, while revenue from operations slightly gained 7.44% to Rs 8670.8 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, gaining 3.59%. It has eased by 2.75% over last one week and edged lower by 2.21% in last one month while the market capitalization of Dr Reddys Laboratories Ltd has slipped by 0.60% and 6.24% in the same period respectively. Profit before tax (PBT) of Dr Reddys Laboratories Ltd stood at Rs 1227.6 crore in Q3 FY26, tanking 29.64% year-on-year, and jumping 121.87% quarter-on-quarter. EBITDA came in at Rs 1574 crore, declining 6.62% YoY and surging by 211.64% sequentially. Total expenses slightly declined by 3.63% to Rs 7493.9 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1661.0 crore, inching up 0.44% YoY, while employee benefits expense was at Rs 1611.9 crore, slipping by 2.40% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 3.19% to Rs 33593.3 crore, while net profit plunged by 27.38% to Rs 4157.6 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 780390% to Rs 5095.1 crore, and PBT tumbled by 29.78% to Rs 5392.7 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 5673.7 crore in FY26, as against Rs 4642.8 crore in FY25. Dr Reddys Laboratories Ltd slipped 4.32% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.52% during the same period.

Dr Reddys Laboratories Ltd share price ticked higher by 0.11% to Rs 1239.0 after the company's net profit jumped 109.64% to Rs 913.2 crore, while revenue from operations slightly gained 7.44% to Rs 8670.8 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, rising 3.59%. It has softened by 2.75% over last one week and softened by 2.21% in last one month while the market capitalization of Dr Reddys Laboratories Ltd has slipped by 0.60% and 6.24% in the same period respectively. Profit before tax (PBT) of Dr Reddys Laboratories Ltd stood at Rs 1227.6 crore in Q3 FY26, plunging by 29.64% year-on-year, and rallying 121.87% quarter-on-quarter. EBITDA came in at Rs 1574 crore, declining 6.62% YoY and jumping 211.64% sequentially. Total expenses marginally dropped 3.63% to Rs 7493.9 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1661.0 crore, growing marginally by 0.44% YoY, while employee benefits expense was at Rs 1611.9 crore, seeing a marginal contraction of 2.40% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 3.19% to Rs 33593.3 crore, while net profit tanked by 27.38% to Rs 4157.6 crore, compared to previous TTM. EBITDA jumped by 780390% to Rs 5095.1 crore, and PBT plunged by 29.78% to Rs 5392.7 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 5673.7 crore in FY26, as against Rs 4642.8 crore in FY25. Dr Reddys Laboratories Ltd declined by 3.19% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.37% during the same period.

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1243, up 1.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.48% on the day, quoting at 22670.45. The Sensex is at 72410.69, down 0.5%. Dr Reddys Laboratories Ltd has gained around 7.67% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 1.12% in last one month and is currently quoting at 26761.65, up 0.45% on the day. The volume in the stock stood at 34.38 lakh shares today, compared to the daily average of 14.98 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1242.5, up 1.5% on the day. Dr Reddys Laboratories Ltd is up 1.58% in last one year as compared to a 7.89% slide in NIFTY and a 25.3% slide in the Nifty Pharma index.The PE of the stock is 153.77 based on TTM earnings ending June 26.

Dr Reddys Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 23448.85. The Sensex is at 74901.08, up 0.5%. Dr Reddys Laboratories Ltd has gained around 1.93% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 2.32% in last one month and is currently quoting at 26909.6, up 0.15% on the day. The volume in the stock stood at 5.57 lakh shares today, compared to the daily average of 14.49 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1212.3, up 0.44% on the day. Dr Reddys Laboratories Ltd is down 6.56% in last one year as compared to a 6.42% slide in NIFTY and a 21.5% slide in the Nifty Pharma index.The PE of the stock is 152.45 based on TTM earnings ending June 26.

Dr. Reddy’s Laboratories Ltd. will hold a board meeting on October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending September 30, 2026, and the trading window for dealing in securities of the company will be closed from September 24, 2026, to October 25, 2026, inclusive.

Dr. Reddy’s Laboratories Ltd. will hold a board meeting on October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending September 30, 2026, and the trading window for dealing in securities of the company will be closed from September 24, 2026, to October 25, 2026, inclusive.

Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1208.6, up 1.99% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74818.76, up 0.71%. Dr Reddys Laboratories Ltd has risen around 1.56% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 8.06 lakh shares today, compared to the daily average of 13.35 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1205.3, up 1.81% on the day. Dr Reddys Laboratories Ltd is down 7.13% in last one year as compared to a 7.1% drop in NIFTY and a 20.91% drop in the Nifty Pharma index.The PE of the stock is 147.31 based on TTM earnings ending June 26.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 375 equity shares of Re. 1/- each to eligible employees on September 10, 2026, following the exercise of stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007, resulting in a total issued share capital of Rs. 83,46,81,285 /- and 83,46,80,285 equity shares.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 4,110 equity shares of Re. 1/- each to eligible employees on August 26, 2026, pursuant to the exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002, resulting in a total issued share capital of Rs. 83,46,80,910 /- and a total issued shares of 83,46,80,910.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced that the U.S. Food and Drug Administration has approved its rituximab biosimilar, developed and manufactured by Dr. Reddy’s Laboratories, for the U.S. market, with Fresenius Kabi holding the exclusive rights to commercialize the product in the United States. The approval follows a recent Pre-License Inspection at the company's biologics manufacturing facility in Bachupally, Hyderabad, and strengthens Dr. Reddy’s global biosimilars portfolio.